Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Apatinib in Neoadjuvant TNBC
NCT04722718Phase 2Unknown
- Start
- Feb 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, Rivoceranib in triple-negative breast cancer (TNBC). Status: unknown.
02
Drugs
sintilimabRivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04722718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722718.